Provided by Tiger Fintech (Singapore) Pte. Ltd.

Therapeutics

25.05
+0.30001.21%
Volume:153.34K
Turnover:3.86M
Market Cap:688.90M
PE:-9.32
High:25.64
Open:25.17
Low:24.78
Close:24.75
Loading ...

Cadrenal Therapeutics FY 2024 GAAP EPS $(8.73) Misses $(7.59) Estimate

Benzinga
·
Yesterday

Press Release: Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Dow Jones
·
Yesterday

Allogene Therapeutics: Q4 Earnings Snapshot

Associated Press Finance
·
Yesterday

Press Release: Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

Dow Jones
·
Yesterday

Press Release: Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

Dow Jones
·
Yesterday

Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results

GlobeNewswire
·
Yesterday

Allogene Therapeutics Q4 EPS $(0.28) Beats $(0.33) Estimate

Benzinga
·
Yesterday

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

GlobeNewswire
·
Yesterday

Tenaya Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Yesterday

Promising Clinical Data and Financial Stability Support Buy Rating for Tenaya Therapeutics Despite Price Target Reduction

TIPRANKS
·
13 Mar

Promising Investment in Werewolf Therapeutics: Strong Financials and Strategic Partnerships Drive Growth Prospects

TIPRANKS
·
13 Mar

Buy Rating for Contineum Therapeutics: Promising Pipeline and Market Opportunities

TIPRANKS
·
13 Mar

Dogwood Therapeutics Launches Registered Direct Offering; Shares Plunge

MT Newswires Live
·
13 Mar

Transcode Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Mar

Allarity Therapeutics Reaches Final Settlement With SEC Over Past Disclosures

MT Newswires Live
·
13 Mar

Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

GlobeNewswire
·
13 Mar